Please login to the form below

Not currently logged in
Email:
Password:

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

Joins as company prepares to advance APF350 to treat side effects of chemotherapy

Jesse Hollingsworth has left Dendreon to join AP Pharma as VP of sales.

The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.

“Over the past several months, AP Pharma has been focused on recruiting key additions to our management team, and Jesse's experience in oncology sales will provide insights into the sales progamme for ... APF350,” said Robert Rosen, AP Pharma's chief commercial officer.

This experience includes Hollingsworth's time as senior director of group purchasing organisation and trade strategy at Dendreon, which developed the prostate cancer vaccine Provenge.

Prior to this role, Hollingsworth was senior director of strategic business development and marketing at ION Solutions.

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

5th March 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics